Literature DB >> 27565519

Novel asymptomatic CNS findings in patients with ACVR1/ALK2 mutations causing fibrodysplasia ossificans progressiva.

Mariasavina Severino1, Marta Bertamino2, Domenico Tortora1, Giovanni Morana1, Sara Uccella3, Renata Bocciardi4,5, Roberto Ravazzolo4,5, Andrea Rossi1, Maja Di Rocco2.   

Abstract

BACKGROUND: Fibrodysplasia ossificans progressiva is an autosomal dominant disorder due to germline mutations of ACVR1/ALK2 causing progressive heterotopic endochondral ossifications. Evidence of central nervous system involvement has emerged only recently.
METHODS: We performed an observational cross-sectional brain MRI study in 13 patients (8 females, mean age 20 years), examining the relationship of clinical and neuroradiological findings.
RESULTS: All patients presented small asymptomatic lesions similar to hamartomas at the level of the dorsal medulla and ventral pons, associated with minor brainstem dysmorphisms and abnormal origin of the vestibulocochlear and facial nerves. The size of the brainstem lesions did not correlate with patient's age (p=0.061), age at first flare-up (p=0.733), severity of disability (p=0.194), history of head trauma (p=0.415) or hearing loss (p=0.237). The radiologic features and the absence of neurological symptoms were consistent with a benign process. Variable signal abnormalities and/or calcifications of the dentate nuclei were noted in all patients, while basal ganglia abnormalities were present in nine subjects. Brain calcifications positively correlated with patient's age (p<0.001) and severity of disability (p=0.002).
CONCLUSIONS: Our data support the hypothesis that the effects of mutation of the ACVR1/ALK2 gene are extended to the central nervous system. Brainstem hamartomatous lesions and dysmorphisms, variably associated with dentate nucleus and basal ganglia signal abnormalities and/or calcifications, may represent useful disease hallmarks. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Brain MRI; Clinical genetics; Diagnostics; Fibrodysplasia Ossificans Progressiva

Mesh:

Substances:

Year:  2016        PMID: 27565519     DOI: 10.1136/jmedgenet-2016-104076

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  5 in total

1.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

2.  Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis.

Authors:  Daniele De Brasi; Francesca Orlando; Valeria Gaeta; Maria De Liso; Fabio Acquaviva; Luigi Martemucci; Augusto Mastrominico; Maja Di Rocco
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

3.  Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.

Authors:  Jerome Fortin; Ruxiao Tian; Ida Zarrabi; Graham Hill; Eleanor Williams; Gonzalo Sanchez-Duffhues; Midory Thorikay; Parameswaran Ramachandran; Robert Siddaway; Jong Fu Wong; Annette Wu; Lorraine N Apuzzo; Jillian Haight; Annick You-Ten; Bryan E Snow; Andrew Wakeham; David J Goldhamer; Daniel Schramek; Alex N Bullock; Peter Ten Dijke; Cynthia Hawkins; Tak W Mak
Journal:  Cancer Cell       Date:  2020-03-05       Impact factor: 31.743

Review 4.  ACVR1 Function in Health and Disease.

Authors:  José Antonio Valer; Cristina Sánchez-de-Diego; Carolina Pimenta-Lopes; Jose Luis Rosa; Francesc Ventura
Journal:  Cells       Date:  2019-10-31       Impact factor: 6.600

5.  Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva.

Authors:  Ke Peng; Keerthana Deepti Karunakaran; Robert Labadie; Miranda Veliu; Chandler Cheung; Arielle Lee; Paul B Yu; Jaymin Upadhyay
Journal:  Orphanet J Rare Dis       Date:  2021-01-30       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.